NUVL vs. TEVA, INSM, SMMT, ITCI, GMAB, RDY, QGEN, VTRS, ASND, and MRNA
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Nuvalent vs. Its Competitors
Teva Pharmaceutical Industries (NYSE:TEVA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.
Nuvalent has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Nuvalent's return on equity.
Teva Pharmaceutical Industries currently has a consensus target price of $24.13, indicating a potential upside of 41.50%. Nuvalent has a consensus target price of $119.60, indicating a potential upside of 48.82%. Given Nuvalent's higher probable upside, analysts clearly believe Nuvalent is more favorable than Teva Pharmaceutical Industries.
In the previous week, Teva Pharmaceutical Industries and Teva Pharmaceutical Industries both had 13 articles in the media. Teva Pharmaceutical Industries' average media sentiment score of 1.15 beat Nuvalent's score of 0.26 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
Teva Pharmaceutical Industries has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 10.2% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Nuvalent has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Nuvalent is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Summary
Teva Pharmaceutical Industries and Nuvalent tied by winning 7 of the 14 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
This page (NASDAQ:NUVL) was last updated on 7/5/2025 by MarketBeat.com Staff
